Anixa Biosciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Anixa Biosciences, Inc. reported positive final Phase 1 clinical trial data for its investigational breast cancer vaccine and continued progress in its CAR-T ovarian cancer therapy, despite ongoing net losses and reliance on future funding.
NASDAQ
Anixa Biosciences reports its fiscal year 2024 results, showcasing advancements in its cancer vaccine and CAR-T therapy programs despite ongoing losses and reliance on future funding.
NASDAQ
Anixa Biosciences' annual report details its financial status and progress in developing cancer vaccines and therapies, while pausing its COVID-19 antiviral program.